GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China Meheco Group Co Ltd (SHSE:600056) » Definitions » Debt-to-EBITDA

China Meheco Group Co (SHSE:600056) Debt-to-EBITDA : 5.67 (As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is China Meheco Group Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

China Meheco Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥4,134 Mil. China Meheco Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥1,879 Mil. China Meheco Group Co's annualized EBITDA for the quarter that ended in Sep. 2024 was ¥1,061 Mil. China Meheco Group Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 5.67.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for China Meheco Group Co's Debt-to-EBITDA or its related term are showing as below:

SHSE:600056' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.29   Med: 1.37   Max: 3.81
Current: 3.81

During the past 13 years, the highest Debt-to-EBITDA Ratio of China Meheco Group Co was 3.81. The lowest was 0.29. And the median was 1.37.

SHSE:600056's Debt-to-EBITDA is ranked worse than
68.67% of 83 companies
in the Medical Distribution industry
Industry Median: 2.15 vs SHSE:600056: 3.81

China Meheco Group Co Debt-to-EBITDA Historical Data

The historical data trend for China Meheco Group Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Meheco Group Co Debt-to-EBITDA Chart

China Meheco Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.91 1.97 3.27 3.05 2.47

China Meheco Group Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.94 2.26 4.63 4.01 5.67

Competitive Comparison of China Meheco Group Co's Debt-to-EBITDA

For the Medical Distribution subindustry, China Meheco Group Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Meheco Group Co's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China Meheco Group Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where China Meheco Group Co's Debt-to-EBITDA falls into.



China Meheco Group Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

China Meheco Group Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2852.019 + 2768.404) / 2275.852
=2.47

China Meheco Group Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4134.24 + 1879.045) / 1060.748
=5.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


China Meheco Group Co  (SHSE:600056) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


China Meheco Group Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of China Meheco Group Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


China Meheco Group Co Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Xiying Street, Floor 18-28, Block B, Building 1, General Times Center, District 1, Fengtai, Beijing, CHN, 100073
China Meheco Group Co Ltd is engaged in the distribution and trading of botanical medicines, medical instruments, and pharmaceuticals. It offers botanic medicines and herbal products, as well as exports of natural medicines, including herbs, spices, plant extracts, bee products, and Chinese traditional medicines. The company's business scope covers the whole industry chain, from research and development, cultivation and processing, manufacturing, distribution, and logistics to international trading, academic promotion, and technical service. The corporation provides trading services for customers in the pharmaceutical and chemical field, covering APIs, preparations, biologicals, blood products, and others.
Executives
Qi Jian Xi senior management
Ni Xiao Ling Director

China Meheco Group Co Headlines

No Headlines